S. 1095: Stop STALLING Act

S. 1095 is a federal bill in the 119th Congress. Currently, brand-name drug companies can submit petitions to the Food and Drug Administration to raise concerns about competing generic drugs, and the agency must review them even if they lack merit, which can delay cheaper medications from reaching… See its sponsors, how members voted, and a plain-English breakdown on PolityLens.